145 mg/m2 NKTR 102
12-102-13
Phase 1 small_molecule completed
Quick answer
145 mg/m2 NKTR 102 for Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment is a Phase 1 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEKTAR THERAPEUTICS
- Indication
- Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed